Literature DB >> 25391509

[Management of malignant pericardial effusion in lung cancer].

G Rousseau-Bussac1, P Crequit1, M Alifano2, C Chouaid3.   

Abstract

Acute pericarditis associated with lung cancer is a relatively frequent complication but is usually not symptomatic unless it causes tamponade. The clinical presentation is classically with dyspnea, thoracic pain, signs of right cardiac failure then left cardiac failure and syncope but it is often a difficult diagnosis in a patient with multi-symptomatic disease. The diagnosis is based on cardiac echography. Toxicity due to radiotherapy or more rarely an infectious etiology must be considered. Clinically significant effusions must be drained because of the high rate of recurrence after a simple aspiration. Drainage is formally indicated when, at echocardiography, the effusion exceeds 20mm in diastole, in cases of tamponade or in cases of compromised hemodynamic status. The formation of a pericardial window at thoracotomy prevents recurrences. Based on old, retrospective, very heterogeneous case series the prognosis, is generally considered to be poor with a median survival which does not exceed 100 days and a one year survival generally lower than 10%. Prognosis is better where diagnosis occurs at an earlier stage allowing regular follow-up and surgical intervention in a non-emergency setting.

Entities:  

Keywords:  Cancer du poumon; Echocardiography; Lung cancer; Metastasis; Métastases; Pericarditis; Péricardite; Échographie cardiaque

Mesh:

Year:  2014        PMID: 25391509     DOI: 10.1016/j.rmr.2014.02.011

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  3 in total

Review 1.  Pericardial Disease Associated with Malignancy.

Authors:  Ryan Schusler; Shari L Meyerson
Journal:  Curr Cardiol Rep       Date:  2018-08-20       Impact factor: 2.931

2.  Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report.

Authors:  Tongpeng Xu; Hao Wu; Shidai Jin; Huang Min; Zhihong Zhang; Yongqian Shu; Wei Wen; Renhua Guo
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

Review 3.  International consensus on severe lung cancer-the first edition.

Authors:  Chengzhi Zhou; Shiyue Li; Jun Liu; Qian Chu; Liyun Miao; Linbo Cai; Xiuyu Cai; Yu Chen; Fei Cui; Yuchao Dong; Wen Dong; Wenfeng Fang; Yong He; Weifeng Li; Min Li; Wenhua Liang; Gen Lin; Jie Lin; Xinqing Lin; Hongbing Liu; Ming Liu; Xinlin Mu; Yi Hu; Jie Hu; Yang Jin; Ziming Li; Yinyin Qin; Shengxiang Ren; Gengyun Sun; Yihong Shen; Chunxia Su; Kejing Tang; Lin Wu; Mengzhao Wang; Huijuan Wang; Kai Wang; Yuehong Wang; Ping Wang; Hongmei Wang; Qi Wang; Zhijie Wang; Xiaohong Xie; Zhanhong Xie; Xin Xu; Fei Xu; Meng Yang; Boyan Yang; Xiangjun Yi; Xiaoqun Ye; Feng Ye; Zongyang Yu; Dongsheng Yue; Bicheng Zhang; Jian Zhang; Jianqing Zhang; Xiaoju Zhang; Wei Zhang; Wei Zhao; Bo Zhu; Zhengfei Zhu; Wenzhao Zhong; Chunxue Bai; Liangan Chen; Baohui Han; Chengping Hu; Shun Lu; Weimin Li; Yong Song; Jie Wang; Caicun Zhou; Jianying Zhou; Yanbin Zhou; Yuichi Saito; Yoshinobu Ichiki; Hitoshi Igai; Satoshi Watanabe; Sara Bravaccini; Alfonso Fiorelli; Francesco Petrella; Takeo Nakada; Piergiorgio Solli; Nikolaos Tsoukalas; Yuki Kataoka; Taichiro Goto; Rossana Berardi; Jianxing He; Nanshan Zhong
Journal:  Transl Lung Cancer Res       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.